• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部无防腐剂的眼科治疗:未满足的临床需求。

Topical preservative-free ophthalmic treatments: an unmet clinical need.

机构信息

Ophthalmology, Department of Surgical, Medical, Molecular Pathology and of Critical Area, University of Pisa, Pisa, Italy.

Ophthalmology Clinic, Department of Medicine and Aging Science, University G. D'Annunzio of Chieti-Pescara, Chieti, Italy.

出版信息

Expert Opin Drug Deliv. 2021 Jun;18(6):655-672. doi: 10.1080/17425247.2021.1860014. Epub 2020 Dec 16.

DOI:10.1080/17425247.2021.1860014
PMID:33280452
Abstract

: The main role of preservatives in eyedrops is to ensure sterility and microbiological integrity of the drug, and to facilitate the penetration of active compounds into the eye. However, several studies documented significant toxic effects induced by preservatives, especially on the ocular surface. Consequently, most of the ophthalmic medications became progressively available in preservative-free (PF) formulations.: We analyzed pre-clinical and clinical studies on PF eyedrops with particular attention to common chronic diseases such as dry eye and glaucoma. We discussed about the pros and cons of using PF eyedrops, in terms of efficacy, safety, and social-economic aspects.: There are still unresolved issues that make hard for PF medications to definitively conquer the drug market. Despite robust pre-clinical evidences of less toxicity, the low number of randomized clinical trials does not permit to state that PF eyedrops have, in clinical practice, a similar efficacy or a higher safety compared to preserved forms. These aspects limit their use to chronic diseases requiring long-term therapies with multiple daily instillations, especially in the presence of concomitant ophthalmic diseases that expose to a risk of ocular surface worsening.

摘要

: 防腐剂在眼药水的主要作用是确保药物的无菌性和微生物完整性,并促进活性化合物渗透到眼睛中。然而,有几项研究记录了防腐剂引起的显著毒性作用,尤其是对眼表面的影响。因此,大多数眼科药物逐渐以无防腐剂(PF)制剂的形式出现。

: 我们分析了 PF 眼药水的临床前和临床研究,特别关注干眼症和青光眼等常见慢性疾病。我们讨论了使用 PF 眼药水在疗效、安全性和社会经济方面的利弊。

: 仍有一些未解决的问题使得 PF 药物难以完全占领药物市场。尽管有大量的临床前毒性较小的证据,但随机临床试验的数量较少,不能说明 PF 眼药水在临床实践中与保存形式相比具有相似的疗效或更高的安全性。这些方面限制了它们在需要长期多次滴眼治疗的慢性疾病中的使用,尤其是在存在可能导致眼表恶化的并存眼病的情况下。

相似文献

1
Topical preservative-free ophthalmic treatments: an unmet clinical need.局部无防腐剂的眼科治疗:未满足的临床需求。
Expert Opin Drug Deliv. 2021 Jun;18(6):655-672. doi: 10.1080/17425247.2021.1860014. Epub 2020 Dec 16.
2
Ocular symptoms and signs with preserved and preservative-free glaucoma medications.使用含防腐剂和不含防腐剂的青光眼药物时的眼部症状和体征。
Eur J Ophthalmol. 2007 May-Jun;17(3):341-9. doi: 10.1177/112067210701700311.
3
The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability.局部无防腐剂制剂治疗青光眼:安全性和耐受性评价。
Expert Opin Drug Saf. 2021 Apr;20(4):453-466. doi: 10.1080/14740338.2021.1873947. Epub 2021 Jan 21.
4
Preservative-free treatment in glaucoma: who, when, and why.青光眼的无防腐剂治疗:对象、时机及原因
Eur J Ophthalmol. 2013 Jul-Aug;23(4):518-25. doi: 10.5301/ejo.5000270. Epub 2013 Mar 7.
5
Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensive Therapy.一项前瞻性、随机、单盲、平行研究,旨在探索含有 0.4%透明质酸和 0.5%牛磺酸的不含防腐剂的眼科溶液对长期接受多种局部降压治疗的青光眼患者眼表的影响。
Adv Ther. 2018 May;35(5):686-696. doi: 10.1007/s12325-018-0699-8. Epub 2018 Apr 23.
6
[Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].[青光眼或高眼压症药物治疗患者的角膜敏感性]
J Fr Ophtalmol. 2011 Dec;34(10):684-90. doi: 10.1016/j.jfo.2011.07.011. Epub 2011 Nov 16.
7
Preservatives in glaucoma medication.青光眼药物中的防腐剂。
Br J Ophthalmol. 2018 Nov;102(11):1497-1503. doi: 10.1136/bjophthalmol-2017-311544. Epub 2018 Jul 4.
8
Topical glaucoma medications - Clinical implications for the ocular surface.局部用青光眼药物 - 对眼表面的临床影响。
Ocul Surf. 2022 Oct;26:19-49. doi: 10.1016/j.jtos.2022.07.007. Epub 2022 Jul 31.
9
Rapid and selective removal of preservative from ophthalmic formulations during eyedrops instillation.滴眼剂滴入过程中从眼科制剂中快速、选择性地去除防腐剂。
Eur J Pharm Biopharm. 2015 Nov;97(Pt A):30-8. doi: 10.1016/j.ejpb.2015.10.004. Epub 2015 Oct 13.
10
Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.眼药水防腐剂的有害作用:对青光眼治疗的影响
Acta Ophthalmol. 2008 Nov;86(7):716-26. doi: 10.1111/j.1755-3768.2008.01250.x. Epub 2008 Jun 3.

引用本文的文献

1
A Review of Acupuncture for the Treatment of Dry Eye Syndrome: Mechanisms, Efficacy, and Clinical Implications.针刺治疗干眼症的综述:作用机制、疗效及临床意义
Int J Gen Med. 2025 Aug 22;18:4647-4658. doi: 10.2147/IJGM.S526265. eCollection 2025.
2
Can the choice of artificial tears harm patients? A narrative review with an overview of the Nordic market.人工泪液的选择会对患者造成伤害吗?一项对北欧市场进行概述的叙述性综述。
Acta Ophthalmol. 2025 Aug;103(5):586-608. doi: 10.1111/aos.17455. Epub 2025 Feb 8.
3
Evidence in Practice: A Review of Real-Life Studies and Clinical Experience with the Preservative-Free Tafluprost (0.0015%) and Timolol (0.5%) Fixed-Dose Combination.
实践中的证据:关于无防腐剂他氟前列素(0.0015%)与噻吗洛尔(0.5%)固定剂量组合的真实研究及临床经验综述
Clin Ophthalmol. 2024 Nov 8;18:3185-3196. doi: 10.2147/OPTH.S479852. eCollection 2024.
4
Is the Advent of New Surgical Procedures Changing the Baseline Features of Patients Undergoing First-Time Glaucoma Surgery?新手术方法的出现是否正在改变首次接受青光眼手术患者的基线特征?
J Clin Med. 2024 Jun 6;13(11):3342. doi: 10.3390/jcm13113342.
5
Managing the ocular surface after glaucoma filtration surgery: an orphan topic.青光眼滤过手术后眼表的处理:一个被忽视的课题。
Graefes Arch Clin Exp Ophthalmol. 2024 Jul;262(7):2039-2056. doi: 10.1007/s00417-023-06333-5. Epub 2023 Dec 13.
6
Changing from preserved, to preservative-free cyclosporine 0.1% enhanced triple glaucoma therapy: impact on ocular surface disease-a randomized controlled trial.从含防腐剂的环孢素 0.1%到不含防腐剂的环孢素 0.1%增强型三联青光眼治疗方案的转换:对眼表疾病的影响——一项随机对照试验。
Eye (Lond). 2023 Dec;37(17):3666-3674. doi: 10.1038/s41433-023-02578-w. Epub 2023 May 23.
7
Challenges and concepts in the diagnosis and management of ocular graft-versus-host disease.眼部移植物抗宿主病诊断与管理中的挑战与概念
Front Med (Lausanne). 2023 Feb 16;10:1133381. doi: 10.3389/fmed.2023.1133381. eCollection 2023.
8
Intravitreal Injectable Hydrogels for Sustained Drug Delivery in Glaucoma Treatment and Therapy.用于青光眼治疗中持续药物递送的玻璃体内可注射水凝胶
Polymers (Basel). 2022 Jun 10;14(12):2359. doi: 10.3390/polym14122359.
9
Treatment of Open-Angle Glaucoma and Ocular Hypertension with the Fixed-Dose Combination of Preservative-Free Tafluprost/Timolol: Clinical Outcomes from Ophthalmology Clinics in Italy.不含防腐剂的他氟前列素/噻吗洛尔固定剂量组合治疗开角型青光眼和高眼压症:来自意大利眼科诊所的临床结果
Clin Ophthalmol. 2022 Jun 1;16:1707-1719. doi: 10.2147/OPTH.S364880. eCollection 2022.
10
Physicochemical Stability of a Novel Tacrolimus Ophthalmic Formulation for the Treatment of Ophthalmic Inflammatory Diseases.一种用于治疗眼部炎症性疾病的新型他克莫司眼用制剂的物理化学稳定性
Pharmaceutics. 2022 Jan 4;14(1):118. doi: 10.3390/pharmaceutics14010118.